新医学2026，Vol.57Issue(6)：662-669,8.DOI:10.12464/j.issn.0253-9802.2025-0411
非典型趋化因子受体ACKR3在肿瘤中的研究进展
Research progress on the atypical chemokine receptor ACKR3 in cancer
摘要
Abstract
Atypical chemokine receptor 3(ACKR3),also known as CXC chemokine receptor 7(CXCR7),has attracted increasing attention for its regulatory roles in the tumor microenvironment.As a high-affinity receptor for CXCL12,ACKR3 participates in malignant processes such as tumor cell proliferation,angiogenesis,invasion and metastasis,and cancer cachexia.ACKR3 is aberrantly over-expressed in multiple solid tumors such as breast cancer,lung cancer and colorectal cancer,suggesting its potential as a diagnostic and prognostic biomarker.Targeting strategies against ACKR3,such as small-molecule inhibitors and nanobody antagonists,have shown promising antitumor activity in preclinical studies.In addition,combined use of ACKR3 inhibitors with endocrine therapy or immune checkpoint inhibitors has preliminarily demonstrated the potential for synergistic effects.This review systematically summarizes the molecular structure of ACKR3,its signaling regulatory mechanisms,functional heterogeneity across different cancers,and advances in ACKR3-targeted therapies.The clinical translational prospects of ACKR3 as a biomarker and therapeutic target are also discussed,providing new perspectives and a study basis for precision anticancer strategies based on ACKR3.关键词
非典型趋化因子受体3/趋化因子/肿瘤微环境/信号通路/靶向治疗Key words
Atypical chemokine receptor 3/Chemokines/Tumor microenvironment/Signal pathway/Targeted therapy引用本文复制引用
孙盼,徐磊,杨涓..非典型趋化因子受体ACKR3在肿瘤中的研究进展[J].新医学,2026,57(6):662-669,8.基金项目
国家自然科学基金地区基金项目(82360467) （82360467）
贵州省科技厅基金项目(黔科合基础-ZK[2023]一般358) （黔科合基础-ZK[2023]一般358）
贵州省卫生健康委科学技术基金项目(gzwkj2023-282) （gzwkj2023-282）
